Development of a cluster of differentiation antibody-based protein microarray

被引:14
作者
Abdo, M
Irving, B
Hudson, P
Zola, H
机构
[1] CSIRO, Div Hlth Sci & Nutr, Parkville, Vic 3052, Australia
[2] Queensland Univ Technol, CRC Diagnost, Brisbane, Qld 4001, Australia
[3] Womens & Childrens Hosp, Child Hlth Res Inst, Adelaide, SA 5006, Australia
关键词
antibody microarray; inflammation; ELISA; C-reactive protein;
D O I
10.1016/j.jim.2005.07.008
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Protein microarrays combine aspects of DNA microarrays and ELISA for the parallel interrogation of a biological sample using a multiplex of protein biomarkers. Here we report the development of a protein microarray consisting of a subset of CD antibodies and CRP. Several preparations (culture supernatant, ascites fluid and purified Ig) of each antibody were used in a forward phase protein microarray. Microarrays were fabricated using a non-contact printer delivering 300 pL (+/- 30 pL) to specific locations on polyacrylamide gel-based substrates. Following production, microarrays were blocked for non-specific binding and incubated with sera conjugated directly with Cy3. Using CRP as a control biomarker, 12 clinical samples (inflammatory conditions and controls) were interrogated using the protein microarray format and results compared to CRP measured by conventional inummoassay. The data obtained from the microarray correlated with CRP assessed by immunoassay. Subsequently CRP 'positive' samples were interrogated for CD antigen expression; which revealed CD25 and CD45RO expression in all samples. Whilst this study focussed on a subset of CD antibodies, it is anticipated that this array could be expanded to include a larger number of CD antibodies and allow screening of sera from multiple conditions in order to identify disease markers. (c) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:3 / 9
页数:7
相关论文
共 17 条
[1]   Toward optimized antibody microarrays:: a comparison of current microarray support materials [J].
Angenendt, P ;
Glökler, J ;
Murphy, D ;
Lehrach, H ;
Cahill, DJ .
ANALYTICAL BIOCHEMISTRY, 2002, 309 (02) :253-260
[2]   C-reactive protein as a risk factor versus risk marker [J].
de Maat, MPM ;
Trion, A .
CURRENT OPINION IN LIPIDOLOGY, 2004, 15 (06) :651-657
[3]  
DUNCAN JI, 1991, CLIN EXP IMMUNOL, V85, P293
[4]  
EKINS RP, 1990, ANAL CHIM ACTA, V227, P73
[5]   Circulating concentrations of soluble L-selectin (CD62L) in patients with primary Sjogren's syndrome [J].
García-Carrasco, M ;
Pizcueta, P ;
Cervera, R ;
Ramos-Casals, M ;
Sisó, A ;
de la Red, G ;
Ingelmo, M ;
Font, J ;
Engel, P .
ANNALS OF THE RHEUMATIC DISEASES, 2000, 59 (04) :297-299
[6]   Protein and antibody microarray technology [J].
Glökler, J ;
Angenendt, P .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2003, 797 (1-2) :229-240
[7]   The telling tail of L-selectin [J].
Ivetic, A ;
Ridley, AJ .
BIOCHEMICAL SOCIETY TRANSACTIONS, 2004, 32 :1118-1121
[8]  
Kozanidou V. I., 2005, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V5, P41, DOI 10.2174/1568008053174741
[9]   Prognostic value of C-reactive protein in patients with stress induced myocardial ischemia [J].
Lombardi, F ;
Tundo, F ;
Terranova, P ;
Battezzati, PM ;
Ramella, M ;
Bestetti, A ;
Tagliabue, L .
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2005, 98 (02) :313-317
[10]   The role of C-reactive protein as a prognostic indicator in advanced cancer. [J].
Mahmoud F.A. ;
Rivera N.I. .
Current Oncology Reports, 2002, 4 (3) :250-255